KENILWORTH, N.J. – Gilead Sciences and Merck today announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people
PRINCETON, N.J.— Dr. Reddy’s announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this
FOSTER CITY, Calif. — Gilead Sciences has temporarily stopped granting patients access to Remdesivir, its experimental drug against the novel coronavirus, citing “overwhelming demand,” the company stated this week. Gilead Sciences said in a statement that it is focused on processing previously approved requests, and that it is developing a new system that it says
FOSTER CITY, Calif. — Gilead Sciences announced that Johanna Mercier will join the company as chief commercial officer, and will become a member of the company’s senior leadership team. Mercier will assume responsibility for the company’s commercial operations effective July 1. Laura Hamill, executive vice president worldwide commercial operations, will be departing from Gilead. Mercier
PISCATAWAY, N.J. — Hetero Drugs, the India-based parent company of Camber Pharmaceuticals, has been honored by Gilead Sciences its commitment to providing access to life-saving medications for chronic hepatitis C patients around the world. Camber said Wednesday that the award from Gilead — a leader in the development of hepatitis C drugs — recognizes Hetero’s
WOONSOCKET, R.I. — CVS Health and Gilead Sciences have reached a deal to make Gilead’s hepatitis C drugs, Harvoni and Sovaldi, the exclusive option for patients on its commercial drug list, as well as for those it manages on health care exchanges, Medicare Part D and Medicaid. The move partly counteracts a recent decision by
